Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer (FLAURA)

November 20, 2017- Interviewed by Steven E. Greer, MD

We interviewed Emory University oncologist Suresh S. Ramalingam, M.D. about his NEJM paper on third-generation oral EGFR inhibitor Tagrisso (osimertinib) by AstraZeneca.

This entry was posted in - NEJM, Cardiac surgery, Emory, Oncology. Bookmark the permalink.

Leave a Reply